Login to Your Account

RNAi Resurgence Continues: Dicerna Closes $60M Series C

By Jennifer Boggs
Managing Editor

Thursday, August 1, 2013

In one of the largest private financings for biotech this year, Dicerna Pharmaceuticals Inc. pulled in $60 million in a Series C round to move into the clinic with its lead RNAi-based candidates against genetically defined targets in disease areas such as oncology.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription